Product Review - Ledipasvir/Sofosbuvir Treatment of Hepatitis C

The purpose of this review is to summarise the main pharmacological and clinical characteristics of ledipasvir/sofosbuvir (Harvoni®), which is an orally-administered interferon-sparing anti-viral drug regimen for use in the treatment of chronic hepatitis C viral infection.

Independent commentary provided by Stephen Pianko,  a Gastroenterologist and Hepatologist with particular expertise in viral hepatitis. Stephen is a consultant Gastroenterologist at Cabrini and Monash Medical Health and is also the Head of Clinical Trials in Gastroenterology at Monash Health.

Please login below to download this issue (PDF)